$300 million agreed upfront for a drug with no disclosed human data, in a deal announced at up to $2.6 billion

Up to $2.6 billion is the headline, and $300 million is the upfront. That is the deal Novo Nordisk and Jiangsu Hengrui Pharmaceuticals announced on Sept. 29, with Novo getting exclusive rights to HRS-1596 outside Greater China. I broke down the gap: roughly $2.3 billion is what remains after the upfront, and tiered royalties on sales come on top of that.

HRS-1596 is a GLP-1/GIP dual receptor agonist designed as a once-weekly oral pill. It has been cleared in China to begin Phase 1 trials in weight management and type 2 diabetes, but no human data has been disclosed.

Hengrui had signed a licensing deal with GSK before this one. GSK's press release on July 28, 2025 put an earlier deal's upfront at $500 million. The potential total was about $12.5 billion, covering up to 12 programs, with milestones payable only if individual programs are optioned and hit their targets. That comparison probably says more about the mechanics of milestone-heavy licensing than about which agreement came out ahead.

Both Hengrui share lines closed higher on Sept. 29. The H share was up 1.88% and the A share up 2.59%. Headlines had reported a rise of more than 5% for the H share during the session, and the intraday high reached HK$47.50. The pullback from that peak to a sub-2% close is easy to interpret as the market discounting the headline total, though one trading day of price action is thin evidence.

The deal is signed but not completed. It requires US antitrust clearance under the HSR Act and is expected to close in the fourth quarter of 2026. That remainder is spread across development, regulatory and commercial milestones, each payable only if its target is met. How do you discount a licensing headline when most of it is milestones?

Inside CNQQ, Health Care sat at 7.3% on the fund's Aug. 31 fact sheet. In the most recently published holdings, Hengrui's A share stood at about 1.29%. CQQQ is built on a China technology sector index that does not reach into pharmaceuticals.